CiMaas Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Buyout/​LBO

  • Investors
  • 1

CiMaas General Information

Description

Developer of immunotherapy designed to cure specific types of cancer. The company's technology engages the immune system for the treatment of a steadily growing population facing cancer that cannot be cured by the current standard of care and focuses on the development of two products: a cancer vaccine using the patient's own immune (dendritic) cells and the production of donor natural killer cells, enabling cancer patients with safe technology taking away several of the severe side-effects of current therapies.

Contact Information

Website
www.cimaas.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Sleperweg 36
  • 6222 NK Maastricht
  • Netherlands
+31 043
Primary Industry
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Sleperweg 36
  • 6222 NK Maastricht
  • Netherlands
+31 043

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CiMaas Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Buyout/LBO 22-Nov-2024 Completed Generating Revenue
3. Bankruptcy: Admin/Reorg 11-Jun-2024 Completed Bankruptcy: Admin/Reorg
2. Debt - General 09-Jan-2021 $2.93M $2.93M Completed Generating Revenue
1. Corporate 08-Feb-2019 Completed Generating Revenue
To view CiMaas’s complete valuation and funding history, request access »

CiMaas Patents

  • 6

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

CiMaas Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025042277-A1 Method of preparing a suspension of mitotically suppressed cells Inactive 23-Aug-2023
EP-4190894-A1 Method for the production of mature dendritic cells in vitro using a bacterial lysate Inactive 03-Dec-2021
US-20230174937-A1 Method for the production of mature dendritic cells in vitro using a bacterial lysate Inactive 03-Dec-2021
ES-2673321-T3 Method for in vitro maturation of dendritic cells Active 12-May-2012
EP-2847321-A1 Method for the in vitro maturation of dendritic cells Active 12-May-2012 A61K40/42
To view CiMaas’s complete patent history, request access »

CiMaas Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CiMaas Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
819 Capital Partners Venture Capital Majority
To view CiMaas’s complete investors history, request access »

Ready to get started?

Request a free trial

CiMaas FAQs

  • When was CiMaas founded?

    CiMaas was founded in 2015.

  • Where is CiMaas headquartered?

    CiMaas is headquartered in Maastricht, Netherlands.

  • What is the size of CiMaas?

    CiMaas has 3 total employees.

  • What industry is CiMaas in?

    CiMaas’s primary industry is Drug Discovery.

  • Is CiMaas a private or public company?

    CiMaas is a Private company.

  • What is CiMaas’s current revenue?

    The current revenue for CiMaas is .

  • How much funding has CiMaas raised over time?

    CiMaas has raised $2.93M.

  • Who are CiMaas’s investors?

    819 Capital Partners has invested in CiMaas.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process